Categories: Health

Bristol Myers Squibb to buy Karuna Therapeutics

Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share.

Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%.

The deal will help expand Bristol Myers’ drug pipeline after competition from a generic offering caused demand for the company’s blood cancer drug Revlimid to tumble in its third quarter.

The boards of directors at both Bristol Myers and Karuna unanimously approved the acquisition, and it is expected to close in the first half of 2024, according to a release.

Karuna develops medications for patients living with neurological and psychiatric conditions. The company’s lead asset is an antipsychotic called KarXT, which is expected to serve as a treatment for adults with schizophrenia beginning in late 2024, the release said.  

“There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space. We expect KarXT to enhance our growth through the late 2020s and into the next decade,” Bristol Myers Squibb CEO Christopher Boerner said in a statement.

KarXT is also being evaluated as a possible treatment for Alzheimer’s disease psychosis and a form of bipolar disorder, according to the release. Karuna CEO Bill Meury said the company’s portfolio “offers advancements in treatment not seen in many years.”

“With Bristol Myers Squibb’s long-standing expertise in developing and commercializing medicines on a global scale and legacy in neuroscience, KarXT and the other assets in our pipeline will be well-positioned to reach those living with schizophrenia and Alzheimer’s disease psychosis,” he said in a statement. 

Citi and Gordon Dyal & Co. advised Bristol Myers on the deal, while Goldman Sachs served as the exclusive advisor for Karuna.

— CNBC’s Annika Kim Constantino contributed to this report.

Don’t miss these stories from CNBC PRO:

Times Reporter

Recent Posts

Results from Merck’s PCSK9 pill suggest a future of ultra-low cholesterol

Merck, the company that brought statins to market nearly 40 years ago, has a new,…

2 hours ago

What travelers need to know about the shutdown, flight cuts and delays

The second day of government-imposed flight cuts took place at 40 of the busiest airports…

8 hours ago

Trump Negotiates with Lilly, Novo Nordisk Could Expand Access to Anti-Obesity Drugs

U.S. President Donald Trump makes an announcement in the Oval Office of the White House…

1 day ago

The ‘Worst Test in Medicine’ is Driving America’s High C-Section Rate

Nearly every woman who gives birth in an American hospital is strapped with a belt…

2 days ago

Pfizer and Novo Nordisk escalate bidding war against Metsera

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the…

4 days ago

The editor received a letter from “Dr. BS’ Many other editors did the same.

Letters to the editor from authors using chatbots are flooding academic journals around the world,…

5 days ago

This website uses cookies.